RS-1
Based on 6 publication(s) in Google Scholar
RS-1 is a RAD51 activator. RS-1 enhances the homologous recombination activity of human RAD51 by promoting the formation of active presynaptic filaments.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.77%
- No. CAS: 312756-74-4
- Fòrmula: C20H16Br2N2O3S
- Peso molecular:524.23
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-107845
SCR7 pyrazineLigase IV Inhibitor/HDR Enhancer -
HY-11006
KU-57788DNA-PK Inhibitor -
HY-15317
RI-1RAD51 Inhibitor -
HY-19334
L755507β3-AR Agonist -
HY-101462
RAD51 Inhibitor B02RAD51 Inhibitor -
HY-10162
OlaparibPARP Inhibitor -
HY-13520
NocodazoleMicrotubule Inhibitor -
HY-111783
AZD-7648DNA-PK Inhibitor -
HY-101570
NedisertibDNA-PK Inhibitor -
HY-136251
BRD0539SpCas9 Inhibitor -
HY-10071
Y-27632ROCK Inhibitor -
HY-12529
Ro-3306CDK1 Inhibitor
Publications Citing Use of MedChemExpress (MCE) RS-1
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
IF
Actividad biológica
Descripciòn
IC50 & Target
In Vitro
RS-1 is a RAD51 activator, stimulating binding of hRAD51 to DNA with Kd ranging from 48 nM to 107 nM in the presence of ATP or ADP and in the absence of a nucleotide cofactor, and such an effect is not via inhibiting its ATPase activity. RS-1 (20 μM) affects the length and helical pitch of hRAD51 protein-DNA complexes. RS-1 (0, 1, 5, 10, 15, 20, and 25 μM) stimulates strand assimilation activity of hRAD51. RS-1 (7.5 μM) promotes resistance of human cells to cross-linking chemotherapy[1]. RS-1 (0, 7.5, 15 μM) increases Cas9-mediated knock-in efficiencies in rabbit embryos[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 312756-74-4
-
Appearance Solid
-
Peso molecular 524.23
-
Fòrmula C20H16Br2N2O3S
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C(Br)C=C1)C2=CC=C(Br)C(S(=O)(NCC3=CC=CC=C3)=O)=C2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Jul 15;16(1):6502. PMID: 40664653 -
Trends Biotechnol
Highly efficient prime editors for mammalian genome editing based on porcine retrovirus reverse transcriptase. [Abstract]2025 Aug 30:S0167-7799(25)00314-2. PMID: 40885667 -
Int J Mol Sci
CRISPR/Cas9 Ribonucleoprotein Delivery Enhanced by Lipo-Xenopeptide Carriers and Homology-Directed Repair Modulators: Insights from Reporter Cell Lines. [Abstract]2025 May 3;26(9):4361. PMID: 40362595
RS-1 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 May 3;26(9):4361. [Abstract]
Cell viability of HeLa-eGFPd2 cells treated with 1738-based Cas9 RNP/ssDNA complexes (18.75 nM, RNP) with various gene correction enhancers, including Pevonedistat (0.5, 1, 2 nM), Rs-1 (1, 2.5, 10 nM), SCR7 (1, 5, 10 nM), M3814 (5, 10, 20 nM), KU-0060648 (0.1, 0.25, 1 nM), and Nu7441 (2.5, 5, 7.5 nM). 1738 refers to treatment with 1738 Cas9 RNP/ssDNA complexes without enhancer. Enhancer abbreviations represent the enhancer name followed by its concentration in nM.
RS-1 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 May 3;26(9):4361. [Abstract]
Total gene editing efficiency (both HDR and NHEJ events) of HeLa-eGFPd2 cells treated with 1738-based Cas9 RNP/ssDNA complexes (18.75 nM, RNP) with various gene correction enhancers, including Pevonedistat (0.5, 1, 2 nM), Rs-1 (1, 2.5, 10 nM), SCR7 (1, 5, 10 nM), M3814 (5, 10, 20 nM), KU-0060648 (0.1, 0.25, 1 nM), and Nu7441 (2.5, 5, 7.5 nM). 1738 refers to treatment with 1738 Cas9 RNP/ssDNA complexes without enhancer. Enhancer abbreviations represent the enhancer name followed by its concentration in nM.
RS-1 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 May 3;26(9):4361. [Abstract]
HDR efficiency of HeLa-eGFPd2 cells treated with 1738-based Cas9 RNP/ssDNA complexes (18.75 nM, RNP) with various gene correction enhancers, including Pevonedistat (0.5, 1, 2 nM), Rs-1 (1, 2.5, 10 nM), SCR7 (1, 5, 10 nM), M3814 (5, 10, 20 nM), KU-0060648 (0.1, 0.25, 1 nM), and Nu7441 (2.5, 5, 7.5 nM). 1738 refers to treatment with 1738 Cas9 RNP/ssDNA complexes without enhancer. Enhancer abbreviations represent the enhancer name followed by its concentration in nM.
-
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
DNA Repair
Transient HR enhancement by RAD51-stimulatory compound confers protection on intestinal rather than hematopoietic tissue against irradiation in mice. [Abstract]2024 Dec:144:103781. PMID: 39520854
RS-1 purchased from MedChemExpress. Usage Cited in: DNA Repair. 2024 Dec:144:103781. [Abstract]
HE staining showing the crypt-villus structure in jejunum in mice treated with different doses of RS-1 (50-150 mg/kg; single dose). Scale bars, 100μm. The results showed that a single administration of the highest dose of RS-1 did not result in significant crypt cell death, nor did it affect cell proliferation.
RS-1 purchased from MedChemExpress. Usage Cited in: DNA Repair. 2024 Dec:144:103781. [Abstract]
The representative images of IF show Olfm4+ cells in the small intestine of NO IR, IR+Veh and IR+RS-1 (100 mg/kg) groups at 48 h or 84 h after TBI. Scale bars (yellow), 200μm. Scale bars (white), 50μm.
-
Solvente y solubilidad
In Vitro:
DMSO : ≥ 100 mg/mL (190.76 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3 mg/mL (5.72 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
CRISPR-Cas9 HDR knock-in/precise editing
CRISPR-Cas9 HDR knock-in uses a guide RNA to direct Cas9 to a genomic target adjacent to a PAM, where Cas9 creates a double-strand break; if a donor DNA template with homology to the cut region is present, cellular HDR can copy the donor sequence into the genome, producing a precise substitution, tag, reporter, or insertion rather than an indel. The readout is the fraction of alleles or cells carrying the intended donor-derived edit, measured by junction PCR, restriction-fragment analysis, Sanger sequencing, amplicon deep sequencing, flow cytometry for reporter knock-in, or clone genotyping; NHEJ indels and partial or non-HDR insertions are measured in parallel because they compete with or confound precise HDR outcomes.
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Jayathilaka K, et al. A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15848-53. [Content Brief]
[2]. Song J, et al. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. Nat Commun. 2016 Jan 28;7:10548. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9076 mL | 9.5378 mL | 19.0756 mL | 47.6890 mL |
| 5 mM | 0.3815 mL | 1.9076 mL | 3.8151 mL | 9.5378 mL | |
| 10 mM | 0.1908 mL | 0.9538 mL | 1.9076 mL | 4.7689 mL | |
| 15 mM | 0.1272 mL | 0.6359 mL | 1.2717 mL | 3.1793 mL | |
| 20 mM | 0.0954 mL | 0.4769 mL | 0.9538 mL | 2.3844 mL | |
| 25 mM | 0.0763 mL | 0.3815 mL | 0.7630 mL | 1.9076 mL | |
| 30 mM | 0.0636 mL | 0.3179 mL | 0.6359 mL | 1.5896 mL | |
| 40 mM | 0.0477 mL | 0.2384 mL | 0.4769 mL | 1.1922 mL | |
| 50 mM | 0.0382 mL | 0.1908 mL | 0.3815 mL | 0.9538 mL | |
| 60 mM | 0.0318 mL | 0.1590 mL | 0.3179 mL | 0.7948 mL | |
| 80 mM | 0.0238 mL | 0.1192 mL | 0.2384 mL | 0.5961 mL | |
| 100 mM | 0.0191 mL | 0.0954 mL | 0.1908 mL | 0.4769 mL |
RS-1 Related Classifications
HY-19793 Related Classifications
Powered by Bioz